Kane Biotech Inc. Secures Funding for Breakthrough Biofilm Technology: Leading the Charge Against Bacteria

In an exciting development for the biotechnology sector, Kane Biotech Inc., widely recognized as THE Biofilm Company, has announced the successful completion of a significant funding round, raising $5 million. This injection of capital will be pivotal in advancing Kane's mission to combat microbial biofilms, which pose a significant challenge across various industries, including healthcare and agriculture. With 81 patents and numerous patents pending, Kane Biotech is at the forefront of innovation, creating smarter solutions to effectively break down biofilms and eliminate harmful bacteria. The freshly secured funds will be utilized to enhance the research and development of their lead products, such as DispersinB® and Aledex™, which have demonstrated remarkable efficacy in biofilm prevention and removal. Additionally, the funding will facilitate the expansion of Kane's commercial efforts, enabling the company to reach broader markets and enhance awareness of their cutting-edge biofilm management technologies. The company's commitment to improving health outcomes and environmental sustainability positions it as a leader in the biotech space, promising not only to revolutionize the way we approach microbial challenges but also to create safer, more effective solutions for consumers and industries alike. As Kane Biotech continues to innovate, shareholders can look forward to a future marked by breakthroughs that not only protect health but also reshape the landscape of biotechnological applications. Available on the TSX Venture Exchange under the symbol "KNE" and the OTCQB Venture Market as “KNBIF”, Kane Biotech is poised to make substantial strides in the fight against bacteria.